A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
NCT05212532
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19 Pneumonia
COVID-19 Respiratory Infection
COVID-19 Acute Respiratory Distress Syndrome
Interventions
DRUG:
EOM613
Sponsor
EOM Pharmaceuticals